INS and fatty liver disease: In addition to its multiple actions that collectively reduce intrahepatic lipid accumulation, such as increasing hepatic insulin sensitivity, reducing hepatic de novo lipogenesis, and increasing mitochondrial fatty acid β-oxidation, FGF21 also activates other mechanisms that contribute to the resolution of hepatic steatosis, inflammation, and possibly fibrosis.